Skip to main content
BHVN logo

BHVN · Biohaven Ltd.

Track BHVN — free
$12.39 -1.26 (-9.23%) At close · Nov 20
Market Cap
$1.87B
Shares
151.06M
Volume · Nov 20 2.39M Avg daily vol (3M) 3.22M

Price & Indicators

 

Key stats

Close
$12.39
Fri 20 Nov
Open
$13.26
Fri 20 Nov
Average volume, 30 days
3.2M
shares a session
Short interest
15.0M
9.9% of shares · 2.9 days to cover
Day range
$12.31$13.75
Open $13.26 Close $12.39
52-week closing range
$8.09$16.95
Close $12.39 26.9% under the high
Short volume, last session
39%
Last earnings
May 27, 2026
Latest filing
10-Q · Oct 29
Price history
Sep 2022 to Nov 2026

Up next

Latest documents

2026
Nov 16
Current report 8-K
Opakalim enrollment paused as two degrader trials advance

Biohaven Ltd. reports the FDA instructed it to pause new opakalim enrollment under a September 4, 2026 partial clinical hold; BHV-1300 entered Phase 3, while BHV-1400 Phase 3 initiation is planned for 2026.

Regulation FD disclosure Read from the first part of this long document
4 source passages
Biohaven Ltd. The FDA ins tructed Biohaven to pause new enrollment until additional clarifying nonclinical s tudies are completed and issued a partial clinical hold letter on September 4, 2026. Lead MoDE Degrader, BHV-1300 Enters Phase 3 BHV-1400 pivotal trial in IgA nephropathy initiating in 2026 Open the document at this passage
Oct 29
Current report 8-K
FDA accepts Vyglxia resubmission for spinocerebellar ataxia

Biohaven's new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia was accepted for review by the FDA, with a user fee goal date in the first quarter of 2027. The company reported a net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026.

Financial results
4 source passages
The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. has assigned a user fee goal date in the first quarter of 2027 Biohaven reported a net loss for the three months ended September 30, 2026 of $129.3 million, or $0.86 per share Cash, cash equivalents, marketable securities and restricted cash as of September 30, 2026, totaled approximately $164.0 million. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
SK Biopharmaceuticals to license Kv7 platform for $400.0 million upfront

In August 2026, Biohaven agreed to license its Kv7 ion channel platform, including BHV-7000, worldwide to SK Biopharmaceuticals. SKBP will pay a non-creditable and non-refundable upfront fee of $400.0 million, $350.0 million at Closing and $50.0 million one year later, plus up to $150.0 million in milestones. An FDA partial clinical hold dated September 4, 2026 pauses new patient enrollment pending additional metabolite nonclinical data.

Net loss $129.28M Diluted EPS -$0.86
Read from the MD&A section
5 source passages
In August 2026, we entered into a License Agreement (the “SKBP License Agreement”) with SK Biopharmaceuticals Co., Ltd. (“SKBP”). to Biohaven’s Kv7 ion channel platform, including BHV-7000 as well as other Kv7 compounds and products covered by the SKBP License Agreement. SKBP will pay us a non-creditable and non-refundable upfront fee of $400.0 million, consisting of $350.0 million payable at the Closing and $50.0 million payable one year after the Closing. Biohaven will also be eligible to receive up to $150.0 million in one-time development and regulatory milestone payments. issued a partial clinical hold letter on September 4, 2026 that pauses new patient enrollment pending the results of additional nonclinical data regarding the metabolite. Open the document at this passage
Oct 22
Current report 8-K
FDA accepts troriluzole SCA resubmission, sets first-quarter 2027 goal date

Biohaven said the FDA accepted its troriluzole resubmission for spinocerebellar ataxia and set a user fee goal date in the first quarter of 2027. The FDA considers the resubmission a complete response to the November 4, 2025 action letter.

Regulation FD disclosure
2 source passages
The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter, and has assigned a user fee goal date in the first quarter of 2027. Open the document at this passage
Oct 15
Current report 8-K Events of Oct 8
Ono licenses IgG degraders for Japan, ASEAN; $80 million upfront

Biohaven entered a Collaboration and License Agreement with Ono Pharmaceutical granting Ono an exclusive, royalty-bearing license to its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and ASEAN countries. Ono will pay an $80 million upfront payment at closing and another $20 million upon a milestone achievement, plus royalties of approximately 20% on net sales. Biohaven keeps rights outside the territory, including the United States, Europe and China.

Entered into a material agreement, Regulation FD disclosure Read from the first part of this long document
7 source passages
entered into a Collaboration and License Agreement (the “License Agreement”) with Ono Pharmaceutical Co., Ltd. (“Ono”) the Company granted Ono an exclusive, royalty-bearing license in Japan, South Korea, Taiwan and the countries of the Association of Southeast Asian Nations (the “Licensed Territory”) Ono will pay the Company a one-time, non-creditable and non-refundable upfront payment of $80 million upon closing another $20 million upon a milestone achievement Ono will pay the Company royalties of approximately 20% on net sales of licensed products in the Licensed Territory The Company retains all rights to the licensed portfolio outside the Licensed Territory, including in the United States, Europe and China. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$542.68M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-25.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$103.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+42.7%
Year over year · more shares
Price change (1Y)
+28.7%
Trailing year
Short interest
9.9%
Latest settlement · 2.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +0%
above
Price vs 50-day avg −8%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 49%
mid-range
Momentum
relative strength
Strong
1-month return −11%
trailing
6-month return +22%
trailing
YTD return +10%
this year
Relative strength +31%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.94% of shares out · ▼ -16.1% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
307 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Fair
EPS growth +26%
Y/Y
Free cash flow $-610.2M
Balance sheet $8.9M
net debt
Quant / Vol
risk profile
Very High
Volatility 83%
annualized · 1-yr
Max drawdown −41%
past year
ATR 8.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 29, 2026
near-term
Near-term cash consideration $400M
Near-term payments up to $100M
upon a milestone achievement anticipated within a year
Another $20 million upon a milestone achievement $20M
Development and regulatory milestone payments up to $150M
upon the closing of the SKBP Agreement
Additional $350.0 million from SKBP $350M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+0% Bullish
Price vs 50-day avg
−8% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
49% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.94% of shares out · ▼ -16.1% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
307 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8 Now $12 · 49% Range high $17
vs 200-day avg +0% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
already randomized patients 600 to date —
cash consideration $400M August 2026 —
combined award $4M August 2026 —
Non-GAAP adjusted net loss non-GAAP $110.7M three months ended September 30, 2026 —
Non-GAAP adjusted net loss per share non-GAAP $0.73 three months ended September 30, 2026 —
participants dosed to date 1,200 to date —
upfront payment received to date $80M October 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BHVN
Biohaven Ltd.
this stock
$1.87B +9.7% — — 9.9%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
307
% held
93.5%
Net QoQ
+58.4K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
57
View
Short & Settlement
Short Interest Falling
Shares short
15.0M
Days to cover
2.9d
Change
-2.9M sh
View
Short Volume
Short vol %
39%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
71
Value
$1.2K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
37.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-738.8M
EPS diluted
$-6.86
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
23

Biohaven Ltd. reports the FDA instructed it to pause new opakalim enrollment under a September 4, 2026 partial clinical hold; BHV-1300 entered Phase 3, while BHV-1400 Phase 3 initiation is planned for 2026.

View
Proposed Sales
Value
$459.7K
Shares
11.0K
Filed
Dec 29, 2023
View
Earnings & Events
Webcasts
Last webcast
May 27, 2026
View
Investor Relations
Latest news
Biohaven's Novel FGFR3-Directed A…
Published
Nov 19, 2026
View

Performance

5D 20D 120D MTD YTD
BHVN -10.4% -10.7% +22.3% -19.7% +9.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -1.8% -1.5% +31.5% -10.9% +8.6%
Key facts CIK 1935979 CUSIP G1110E107 13F (30d) 298 filings 272 filers Visit website Investor relations